Pharmaceuticals, Biotechnology & Life Sciences

Discover how GRAIL’s liquid‑biopsy tech is reshaping cancer diagnostics and boosting stock performance—key insights for investors and patients alike.

WEIGUANG BIOLOGICAL sees trading surge as AI‑driven drug development fuels biotech optimism and a sector rebound.

Discover how Anavex Life Sciences Corp. is driving precision genetic medicine for neurological disorders, its latest proxy filing, and market outlook.

Oxford Nanopore Technologies faces market volatility amid U.S. Iran sanctions, balancing R&D, capital allocation, and geopolitical risks to sustain growth.

Discover Satellos Bioscience’s cutting‑edge skeletal muscle regeneration therapies, market insights, and growth prospects for investors and patients.

Alkermes PLC: Ireland‑based biotech tackling addiction, schizophrenia, depression & diabetes with cutting‑edge CNS therapies. Explore growth, stock trends & future breakthroughs.

Repligen CEO boosts stake, signaling confidence in biotech growth—inside look at ownership change, stock options, and future potential.

Moderna’s Phase‑III melanoma vaccine shows 23% overall survival boost, sparking a 179% share surge and marking a pivotal shift toward mRNA oncology.

GRI Bio reveals promising Phase‑2a data for its NKT‑targeted antifibrotic GRI‑0621, showing improved lung function, biomarker reduction, and a strong safety profile for IPF patients.

Discover how Annovis Bio tackles neurodegenerative diseases and orphan conditions, its conference insights, stock outlook, and commitment to innovative therapies.